Education
About Us
Working with TipRanks
Follow Us
Omada Health, Inc. (OMDA)
NASDAQ:OMDA
OMDA Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OMDA Stock 12 Month Forecast
Average Price Target
$29.14
▲(90.33% Upside)
| Highest Price Target$32.00 | Average Price Target$29.14 | Lowest Price Target$27.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$32
Buy
109.01%
Upside
Reiterated
11/17/25
Omada Health's Strategic Growth and Profitability: A Buy Rating by Craig HettenbachWe hosted meetings with Sean Duffy (Co-Founder and Cook (CFO) and Allan Kells (IR) last week. Investors were focused mostly on the new GLP-1 prescribing initiative, how the company is utilizing AI, operating leverage in the model, 2026 selling season, and the competitive landscape. What investors didn't ask but that we think they should be asking: Omada's traction in diabetes and hypertension programs and implications for growth and margins. Top takeaways from our meetings: 1. GLP-1 prescribing provides another lever of upside to growth and is expected to be accretive to margins. Omada will partner with providers to integrate prescribing capabilities into its app.
Evercore ISI
$28
Buy
82.89%
Upside
Reiterated
11/17/25
J.P. Morgan
$31→$32
Buy
109.01%
Upside
Reiterated
11/12/25
BMO Capital
$27
Buy
76.36%
Upside
Initiated
11/12/25
Barclays
$28→$29
Buy
89.42%
Upside
Reiterated
11/07/25
Canaccord Genuity
$28
Buy
82.89%
Upside
Reiterated
11/07/25
Needham
$24→$28
Buy
82.89%
Upside
Reiterated
11/07/25
Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy RatingWe are reiterating our Buy rating while raising our PT to $28 following the company's strong 3Q25 results in which revenue and adj. EBITDA came in nicely ahead of expectations driven by an impressive number of member adds which highlights the strength of Omada's engagement initiatives. However, Omada isn't just a 2025 success story, in our view, as strong selling season momentum has created double-digit growth in client wins, while OMDA's newest channel relationship is already bearing fruit with a number of multi- condition customer wins. We believe this sets OMDA up well heading into FY26 to continue its strong profitable growth trajectory on the back of what is expected to be a near-50% growth year. We remain buyers on strength as we expect OMDA to gain share in a multi-year GLP-1 driven cardiometabolic health adoption cycle.
Robert W. Baird
$24
Hold
56.76%
Upside
Initiated
09/04/25
Goldman Sachs
$29
Buy
89.42%
Upside
Initiated
06/30/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$32
Buy
109.01%
Upside
Reiterated
11/17/25
Omada Health's Strategic Growth and Profitability: A Buy Rating by Craig HettenbachWe hosted meetings with Sean Duffy (Co-Founder and Cook (CFO) and Allan Kells (IR) last week. Investors were focused mostly on the new GLP-1 prescribing initiative, how the company is utilizing AI, operating leverage in the model, 2026 selling season, and the competitive landscape. What investors didn't ask but that we think they should be asking: Omada's traction in diabetes and hypertension programs and implications for growth and margins. Top takeaways from our meetings: 1. GLP-1 prescribing provides another lever of upside to growth and is expected to be accretive to margins. Omada will partner with providers to integrate prescribing capabilities into its app.
Evercore ISI
$28
Buy
82.89%
Upside
Reiterated
11/17/25
J.P. Morgan
$31→$32
Buy
109.01%
Upside
Reiterated
11/12/25
BMO Capital
$27
Buy
76.36%
Upside
Initiated
11/12/25
Barclays
$28→$29
Buy
89.42%
Upside
Reiterated
11/07/25
Canaccord Genuity
$28
Buy
82.89%
Upside
Reiterated
11/07/25
Needham
$24→$28
Buy
82.89%
Upside
Reiterated
11/07/25
Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy RatingWe are reiterating our Buy rating while raising our PT to $28 following the company's strong 3Q25 results in which revenue and adj. EBITDA came in nicely ahead of expectations driven by an impressive number of member adds which highlights the strength of Omada's engagement initiatives. However, Omada isn't just a 2025 success story, in our view, as strong selling season momentum has created double-digit growth in client wins, while OMDA's newest channel relationship is already bearing fruit with a number of multi- condition customer wins. We believe this sets OMDA up well heading into FY26 to continue its strong profitable growth trajectory on the back of what is expected to be a near-50% growth year. We remain buyers on strength as we expect OMDA to gain share in a multi-year GLP-1 driven cardiometabolic health adoption cycle.
Robert W. Baird
$24
Hold
56.76%
Upside
Initiated
09/04/25
Goldman Sachs
$29
Buy
89.42%
Upside
Initiated
06/30/25
Best Analysts Covering Omada Health, Inc.
1 Month
xxx
Success Rate
1/3 ratings generated profit
Average Return
+2.60%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of +2.60% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+2.20%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.20% per trade.
1 Year
Success Rate
0/3 ratings generated profit
Average Return
-18.27%
reiterated a buy rating last month
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -18.27% per trade.
2 Years
xxx
Success Rate
0/3 ratings generated profit
Average Return
-18.27%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -18.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OMDA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
2
1
1
2
2
Buy
15
15
10
12
12
Hold
1
2
3
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
18
14
19
20
Each month's total comprises the sum of three months' worth of ratings.
OMDA Financial Forecast
OMDA Stock Forecast FAQ
What is OMDA’s average 12-month price target, according to analysts?
Based on analyst ratings, Omada Health, Inc.’s 12-month average price target is 29.14.
What is OMDA’s upside potential, based on the analysts’ average price target?
Omada Health, Inc. has 90.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OMDA a Buy, Sell or Hold?
Omada Health, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Omada Health, Inc.’s price target?
The average price target for Omada Health, Inc. is 29.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $27.00. The average price target represents 90.33% Increase from the current price of $15.31.
The highest analyst price target is $32.00 ,the lowest forecast is $27.00. The average price target represents 90.33% Increase from the current price of $15.31.
What do analysts say about Omada Health, Inc.?
Omada Health, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of OMDA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.